Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy

阿那曲唑 来曲唑 医学 富维斯特朗 内科学 乳腺癌 肿瘤科 安慰剂 芳香化酶抑制剂 危险系数 临床终点 癌症 随机对照试验 雌激素受体 三苯氧胺 置信区间 病理 替代医学
作者
Elif Hindié
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (9): e356-e356 被引量:4
标识
DOI:10.1016/s1470-2045(23)00360-1
摘要

In the phase 3 trial DAWNA-2, reported by Pin Zhang and colleagues, 1 Zhang P Zhang Q Tong Z et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023; 24: 646-657 Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar the CDK4/6 inhibitor dalpiciclib was investigated at 42 hospitals in China as a first-line treatment in combination with endocrine therapy (letrozole or anastrozole) in patients with hormone receptor-positive, HER2-negative advanced breast cancer. The primary endpoint of progression-free survival was met, with a median PFS of 30·6 months (95% CI 30·6–not reached) in the dalpiciclib group versus 18·2 months (16·5–22·5) in the placebo plus endocrine therapy group (stratified hazard ratio [HR] 0·51 [95% CI 0·38–0·69]; one-sided log-rank p<0·0001). 1 Zhang P Zhang Q Tong Z et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023; 24: 646-657 Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar In a previous trial, DAWNA-1, dalpiciclib showed efficacy in combination with fulvestrant in patients progressing after first-line endocrine therapy (median progression-free survival 15·7 months vs 7·2 months with placebo plus fulvestrant; HR 0·42, p<0·0001). 2 Xu B Zhang Q Zhang P et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27: 1904-1909 Crossref PubMed Scopus (33) Google Scholar The first-line use of this treatment means a longer exposure to the side-effects of CDK4/6 inhibitors. Notably, grade 3 or 4 neutropenia occurred in 86% of patients in the dalpiciclib group. 1 Zhang P Zhang Q Tong Z et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023; 24: 646-657 Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar High rates of neutropenia also have been shown to occur with palbociclib and ribociclib, and the Asian population has a higher susceptibility to CDK4/6 inhibitors. 3 O'Sullivan CC Clarke R Goetz MP Robertson J Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncol. 2023; (published online June 29.)https://doi.org/10.1001/jamaoncol.2023.2000 Crossref Google Scholar Additionally, abemaciclib, another CDK4/6 inhibitor, is associated with high rates of gastrointestinal symptoms. 3 O'Sullivan CC Clarke R Goetz MP Robertson J Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncol. 2023; (published online June 29.)https://doi.org/10.1001/jamaoncol.2023.2000 Crossref Google Scholar Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy – Author's replyWe appreciate Elif Hindié's interest in the DAWNA-2 study, which focuses on the optimal sequencing of CDK4/6 inhibitors in patients with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. CDK4/6 inhibitors have shown improved outcomes in both first-line and second-line treatments, but comparative evidence supporting their sequencing is absent, despite guidelines recommending their use as a first-line treatment.1 Full-Text PDF

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阳光完成签到,获得积分10
刚刚
带路完成签到,获得积分10
刚刚
烟花的应助被梓齊采纳,获得10
刚刚
小小的飞机完成签到,获得积分10
刚刚
俊逸的伟帮完成签到,获得积分10
1秒前
1秒前
Hw完成签到,获得积分10
1秒前
虞山小王子完成签到,获得积分20
1秒前
2秒前
研友_VZG7GZ的应助被平常的雁凡采纳,获得10
2秒前
马家沟大水鸭完成签到,获得积分10
2秒前
RegSequ完成签到,获得积分10
2秒前
阿申爱乐的应助被CharlieMason820采纳,获得30
3秒前
无极微光的应助被lolly采纳,获得20
3秒前
kukuluo完成签到,获得积分10
3秒前
3秒前
爱学习的小i完成签到 ,获得积分10
3秒前
tuoeryao完成签到,获得积分10
3秒前
ccshi完成签到,获得积分10
3秒前
4秒前
NexusExplorer的应助被欣喜紫霜采纳,获得10
4秒前
丁一完成签到,获得积分0
4秒前
una完成签到 ,获得积分10
4秒前
花开花落花无悔完成签到 ,获得积分10
4秒前
4秒前
czy完成签到,获得积分10
5秒前
封似狮完成签到,获得积分10
5秒前
yu完成签到,获得积分10
5秒前
5秒前
卢某某发布了新的文献求助10
5秒前
5秒前
追悟完成签到,获得积分10
5秒前
QTMX完成签到,获得积分20
5秒前
5秒前
宋宋syi完成签到 ,获得积分10
5秒前
科研通AI6.3的应助被无字诉题采纳,获得10
5秒前
ZiZi完成签到 ,获得积分10
6秒前
Firsterchao的应助被tszjw168采纳,获得10
6秒前
桃桃完成签到,获得积分10
7秒前
chancute完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162